A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) | MicrobiomeTrials← Back to trialsNCT07310095
A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2025-12-30Est. Completion: 2027-09-15
Enrollment target: 78 participants Locations- The First Affiliated Hospital Sun Yat sen University, Guangzhou, China
- The Sixth Affiliated Hospital Sun Yat sen University, Guangzhou, China
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, China
- The First Affiliated Hospital of Anhui Medical University, Hefei, China
- Ruijin Hospital, Shanghai, China
Other microbiome trials you might be interested in
Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis
Background:
Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in …
Bethesda, United StatesEst. completion Jun 1, 2036
Inflammatory Bowel Disease
Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the…
Chicago, United StatesEst. completion Sep 1, 2026
Phase 4
Recruiting
This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of standard-dose tumor necrosis …
Guangzhou, ChinaEst. completion Dec 31, 2028